HIF2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index.
Abstract
Approximately 50% of cancer patients receive radiation treatment, either alone or in combination with other therapies. Tumor hypoxia has long been associated with resistance to radiation therapy. Moreover, the expression of hypoxia inducible factors HIF1α and/or HIF2α correlates with poor prognosis in many tumors. Recent evidence indicates that HIF1α expression can enhance radiation-induced apoptosis in cancer cells. We demonstrate here that HIF2α inhibition promotes tumor cell death and, in contrast to HIF1α, enhances the response to radiation treatment. Specifically, inhibiting HIF2α expression augments p53 activity, increases apoptosis, and reduces clonogenic survival of irradiated and non-irradiated cells. Moreover, HIF2α inhibition promotes p53-mediated responses by disrupting cellular redox homeostasis, thereby permitting reactive oxygen species (ROS) accumulation and DNA damage. These results correlate with altered p53 phosphorylation and target gene expression in untreated human tumor samples and show that HIF2α likely contributes to tumor cell survival including during radiation therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Apart from canonical HRE-mediated transcription, the HIF isoforms differentially modulate signaling pathways through interaction with proteins that do not contain PAS domains, such p53, the c-MYC proto-oncogene, β-catenin and the Notch intracellular domain (Fig. 2A) [11–15].”
From Revisiting the HIF switch in the tumor and its immune microenvironment. (2022) · cites this paper as [15]
In the citing paper
“HIF-2α seems to have an opposing effect on p53 (at least in ccRCC) since HIF-2α inhibits p53 in an Mdm2-independent manner, thereby providing therapeutic opportunities via HIF-2α inhibition (Bertout et al., 2009;Roberts et al., 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Bertout et al., 2009
In the citing paper
“HIF-2α contributes to tumor cell survival after IR, and HIF-2α inhibition can increase the IR effect by activating the p53 pathway and increasing apoptosis (Bertout et al., 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Bertout et al., 2009
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717 · cited 1×
“Moreover, HIF1 and/or HIF2 expression has been associated with increased tumor vascularization and poor prognosis of numerous cancers such as breast, ovarian, and non-small cell lung cancer (2, 4).”
BackgroundThe tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“To assess the effect of HIF2 on the p53 pathway, we selected two VHL-deficient human ccRCC cell lines that express HIF2 (A498 and 786-O) under normoxic conditions (18).”
MethodRegulation of angiogenesis by hypoxia: role of the HIF system
Pugh, C. W., & Ratcliffe, P. J. (2003) · Nature Medicine · doi:10.1038/nm0603-677 · Cited by 2,520 · cited 1×
“Solid tumors are characterized by oncogenic signaling and hypoxic microenvironments that promote HIF accumulation (3).”
BackgroundThe impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365 · cited 3×
“Moreover, HIF1 and/or HIF2 expression has been associated with increased tumor vascularization and poor prognosis of numerous cancers such as breast, ovarian, and non-small cell lung cancer (2, 4).”
BackgroundSelf-citationHeme oxygenase-1: unleashing the protective properties of heme
Otterbein, L. E., Soares, M. P., Yamashita, K., & Bach, F. H. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00181-9 · Cited by 1,166
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940 · cited 2×
“It is becoming increasingly clear that HIF1 and HIF2 can have distinct effects in tumor cells (6, 16).”
BackgroundStabilization of wild-type p53 by hypoxia-inducible factor 1α
An, W. G., Kanekal, M., Simon, M. C., Maltepe, E., Blagosklonny, M. V., & Neckers, L. M. (1998) · Nature · doi:10.1038/32925 · Cited by 827 · cited 1×
“Furthermore, HIF1 has been shown to complex with p53 and promote its stability (14, 15).”
BackgroundSelf-citationHIF-2α Promotes Hypoxic Cell Proliferation by Enhancing c-Myc Transcriptional Activity
Gordan, J. D., Bertout, J. A., Hu, C.-J., Diehl, J. A., & Simon, M. C. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.02.006 · Cited by 781 · cited 2×
“It is increasingly clear that HIF1 and HIF2 have contrasting roles in tumor cell biology, as evidenced by their opposing regulation of c-Myc (16).”
BackgroundSelf-citationHolmquist-Mengelbier, L., Fredlund, E., Löfstedt, T., Noguera, R., Navarro, S., Nilsson, H., Pietras, A., Vallon-Christersson, J., Borg, Å., Gradin, K., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.026 · Cited by 735 · cited 1×
“Of note, in mouse xenograft models, HIF2 (and not HIF1 ) expression is crucial for growth of clear cell renal cell carcinoma (ccRCC) (5, 6) and neuroblastoma (7) tumors.”
BackgroundThe complexity of p53 stabilization and activation
Lavin, M. F., & Gueven, N. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401925 · Cited by 701 · cited 2×
“Following stress stimuli, p53 is activated through a variety of post-translational modifications, including phosphorylation on serine 15 (9).”
BackgroundInhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611 · cited 1×
“Of note, in mouse xenograft models, HIF2 (and not HIF1 ) expression is crucial for growth of clear cell renal cell carcinoma (ccRCC) (5, 6) and neuroblastoma (7) tumors.”
BackgroundScortegagna, M., Ding, K., Oktay, Y., Gaur, A., Thurmond, F., Yan, L.-J., Marck, B. T., Matsumoto, A. M., Shelton, J. M., Richardson, J. A., et al. (2003) · Nature Genetics · doi:10.1038/ng1266 · Cited by 496 · cited 4×
“As HIF2 inhibits reactive oxygen species (ROS) accumulation in other contexts (17), we hypothesized that HIF2 suppresses p53 activation by reducing ROS levels generated from normal metabolic processes as well as IR treatment, promoting tumor cell survival.”
BackgroundResultInfluentialHIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
Gordan, J. D., Lal, P., Dondeti, V. R., Letrero, R., Parekh, K. N., Oquendo, C. E., Greenberg, R. A., Flaherty, K. T., Rathmell, W. K., Keith, B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.016 · Cited by 493 · cited 3×
“We observed three categories of HIF expression in these tumors (29): VHL wild type with no HIF expression (‘‘VHL WT’’), VHL-deficient tumors expressing HIF1 and HIF2 (‘‘H1H2’’), and VHL-deficient tumors expressing only HIF2 (‘‘H2’’).”
BackgroundSelf-citationHypoxia-inducible factors: central regulators of the tumor phenotype
Gordan, J. D., & Simon, M. C. (2007) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2006.12.006 · Cited by 453 · cited 1×
“These transcription factors promote the expression of over 200 genes (1) and are heterodimers consisting of either HIF1 or HIF2 bound to the HIF /ARNT subunit.”
BackgroundSelf-citationHainaut, P. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.205 · Cited by 446 · cited 1×
“TP53 is a tumor suppressor that is mutated or silenced in a majority of human cancers (8).”
BackgroundUchida, T., Rossignol, F., Matthay, M. A., Mounier, R., Couette, S., Clottes, E., & Clerici, C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400461200 · Cited by 428
Chang, T.-S., Cho, C.-S., Park, S., Yu, S., Kang, S. W., & Rhee, S. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407707200 · Cited by 388
Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity
Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.016 · Cited by 374 · cited 3×
“Dewhirst and colleagues reported that HIF1 stimulates p53 phosphorylation and p53-dependent cell death in cancer cells (13).”
BackgroundInfluentialTissue-specific induction of p53 targets in vivo.
Fei, P., Bernhard, E. J., & El‐Deiry, W. S. (2002) · PubMed · Cited by 278
Evolutionary and Structural Insights Into the Multifaceted Glutathione Peroxidase (Gpx) Superfamily
Toppo, S., Vanin, S., Bosello, V., & Tosatto, S. C. E. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2008.2057 · Cited by 259
p53 Stabilization and Transactivation by a von Hippel-Lindau Protein
Roe, J.-S., Kim, H., Lee, S.-M., Kim, S.-T., Cho, E.-J., & Youn, H.-D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.04.006 · Cited by 237 · cited 1×
“We also chose these lines to avoid the confounding factors of HIF1 and pVHL expression, described to promote p53 stabilization and activity (20).”
BackgroundZimmer, M., Ebert, B. L., Neil, C., Brenner, K., Papaioannou, I., Melas, A., Tolliday, N., Lamb, J., Pantopoulos, K., Golub, T., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.12.004 · Cited by 191 · cited 2×
“These results strongly encourage the development of specific HIF2 inhibitors for use in tumors with an intact p53 stress response pathway (12).”
BackgroundOutcomes of p53 activation - spoilt for choice
Vousden, K. H. (2006) · Journal of Cell Science · doi:10.1242/jcs.03293 · Cited by 189 · cited 2×
“Of note, it is typical to observe changes in some but not all p53 targets because of factors such as cellular context, posttranslational modifications, availability of specific transcriptional cofactors, and stress category and dosage (22, 30, 31).”
BackgroundGenetic evidence for a tumor suppressor role of HIF-2α
Acker, T., Diez-Juan, A., Aragones, J., Tjwa, M., Brusselmans, K., Moons, L., Fukumura, D., Moreno-Murciano, M. P., Herbert, J.-M., Burger, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.003 · Cited by 184 · cited 1×
“In addition, although HIF2 function can depend on tumor type (32), we observed similar effects of HIF2 on p53 in lung carcinoma and ccRCC.”
BackgroundInhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
Melillo, G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0235 · Cited by 166 · cited 1×
“With the emergence of HIF inhibitors (11, 12) and their potential use in cancer therapy, it is important to accurately predict the response of HIF -expressing tumor cells to treatment.”
BackgroundBinding of Natively Unfolded HIF-1α ODD Domain to p53
Sánchez‐Puig, N., Veprintsev, D. B., & Fersht, A. R. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.019 · Cited by 116
p53 Pathway in Renal Cell Carcinoma Is Repressed by a Dominant Mechanism
Gurova, K. V., Hill, J. E., Razorenova, O. V., Chumakov, P. M., & Gudkov, A. V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1541 · Cited by 108 · cited 1×
“Although many tumors select for TP53 mutations, p53 pathway inhibition can also contribute to tumor progression (10).”
BackgroundDirect evidence of caeruloplasmin antioxidant properties
Atanasiu, R., Stea, D., Mateescu, M. A., Vergely, C., Dalloz, F., Briot, F., Maupoil, V., Nadeau, R. A., & Rochette, L. (1998) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006945713860 · Cited by 77
p53 binding to the p21 promoter is dependent on the nature of DNA damage
Bodzak, E., Blough, M. D., Lee, P. W. K., & Hill, R. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6440 · Cited by 59 · cited 1×
“Of note, it is typical to observe changes in some but not all p53 targets because of factors such as cellular context, posttranslational modifications, availability of specific transcriptional cofactors, and stress category and dosage (22, 30, 31).”
BackgroundBianco, N. R., Perry, G. L., Smith, M. A., Templeton, D. J., & Montano, M. M. (2003) · Molecular Endocrinology · doi:10.1210/me.2002-0382 · Cited by 52
XIAP regulates intracellular ROS by enhancing antioxidant gene expression
Resch, U., Schichl, Y. M., Sattler, S., & de Martin, R. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.07.142 · Cited by 41
Expression of p53 in renal carcinoma cells is independent of pVHL
Stickle, N. H., Cheng, L. S., Watson, I. R., Alon, N., Malkin, D. M., Irwin, M. S., & Ohh, M. (2005) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2005.02.016 · Cited by 28
Cited by
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380
Self-citationThe role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy
Muz, B., de la Puente, P., Azab, F., & Azab, A. K. (2015) · Hypoxia · doi:10.2147/hp.s93413 · Cited by 2,066
“Silencing of HIF-1α with siRNA in mouse embryonic fibroblasts increased susceptibility to irradiation;(106) and also, HIF-2α inhibition was shown to enhance radiation-induced apoptosis due to HIF-2-mediated increase of p53 activity and accumulation of ROS, thus DNA damage (Figure 2).(108)”
BackgroundHIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Self-citationHypoxia-Induced Angiogenesis: Good and Evil
Krock, B. L., Skuli, N., & Simon, M. C. (2011) · Genes & Cancer · doi:10.1177/1947601911423654 · Cited by 1,180
Self-citationGupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4414 · Cited by 732
“For example, in a recent study, HIF-2 a inhibition was found to enhance the response of lung cancer cells to radiation treatment that was associated with an accumulation of ROS and increased p53 activity (32).”
Metadata
- Authors
- Bertout, J. A., Majmundar, A. J., Gordan, J. D., Lam, J. C., Ditsworth, D., Keith, B., Brown, E. J., Nathanson, K. L., & Simon, M. C.
- Affiliations
- Abramson Cancer Center (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Simon, M. Celeste
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-08-25
- Volume
- 106
- Issue
- 34
- Pages
- 14391-14396
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2726037
- OpenAlex
- W2009520390
- Semantic Scholar
- a0b2ebcc5cc1a45ff8bd1fc8fa4b3e6d84b1fe85
- Cited by
- 196
- References
- 33
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 7 · 2023: 7 · 2022: 13 · 2021: 20 · 2020: 8 · 2019: 9 · 2018: 13 · 2017: 10 · 2016: 16 · 2015: 20 · 2014: 11 · 2013: 15 · 2012: 10
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (P01CA104838, CA104838, R25CA101871)
- Abramson Family Cancer Research Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- HIF-2α, HIF-1α, p53 pathway, radiotherapy response, tumor hypoxia, apoptosis, redox homeostasis, reactive oxygen species, DNA damage, p53 phosphorylation, clonogenic survival, radiosensitivity
- MeSH terms
- Endothelial PAS Domain-Containing Protein 1, Cell Cycle, DNA Damage, Humans, Microscopy, Fluorescence, Neoplasms, Proto-Oncogene Proteins, Radiation, Ionizing, Immunoblotting, Signal Transduction, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Cell Death, Reactive Oxygen Species, Reverse Transcriptase Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, RNA Interference, Cell Line, Tumor, Apoptosis Regulatory Proteins, Basic Helix-Loop-Helix Transcription Factors, Basic Helix-Loop-Helix Proteins, Caspase 3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.